These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 20112435

  • 1. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril.
    Johnson ES, Weinstein JR, Thorp ML, Platt RW, Petrik AF, Yang X, Anderson S, Smith DH.
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):266-72. PubMed ID: 20112435
    [Abstract] [Full Text] [Related]

  • 2. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME.
    J Am Heart Assoc; 2017 Jul 19; 6(7):. PubMed ID: 28724651
    [Abstract] [Full Text] [Related]

  • 3. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A.
    J Am Geriatr Soc; 2002 Jul 19; 50(7):1297-300. PubMed ID: 12133029
    [Abstract] [Full Text] [Related]

  • 4. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, Rogers K, Gallagher M.
    PLoS One; 2019 Jul 19; 14(3):e0213192. PubMed ID: 30845156
    [Abstract] [Full Text] [Related]

  • 5. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P, VA NEPHRON-D Investigators.
    Clin J Am Soc Nephrol; 2009 Feb 19; 4(2):361-8. PubMed ID: 19118120
    [Abstract] [Full Text] [Related]

  • 6. Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan).
    Zanabli AR, Yango A, Dworkin L.
    S D J Med; 2004 Jun 19; 57(6):227-31. PubMed ID: 15253477
    [Abstract] [Full Text] [Related]

  • 7. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
    Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA, Rydén L.
    Arch Intern Med; 2001 Jan 22; 161(2):165-71. PubMed ID: 11176729
    [Abstract] [Full Text] [Related]

  • 8. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
    Parikh RV, Nash DM, Brimble KS, Markle-Reid M, Tan TC, McArthur E, Khoshniat-Rad F, Sood MM, Zheng S, Pravoverov L, Nesrallah GE, Garg AX, Go AS.
    Circ Cardiovasc Qual Outcomes; 2020 Sep 22; 13(9):e006415. PubMed ID: 32873054
    [Abstract] [Full Text] [Related]

  • 9. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S, Khan A, Vincent A, Lau K.
    Am J Med Sci; 2008 Oct 22; 336(4):330-5. PubMed ID: 18854676
    [Abstract] [Full Text] [Related]

  • 10. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study.
    Adelborg K, Nicolaisen SK, Hasvold P, Palaka E, Pedersen L, Thomsen RW.
    PLoS One; 2019 Oct 22; 14(6):e0218739. PubMed ID: 31226134
    [Abstract] [Full Text] [Related]

  • 11. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.
    Kidney Int Suppl; 2002 Dec 22; (82):S47-52. PubMed ID: 12410855
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?
    Reardon LC, Macpherson DS.
    Arch Intern Med; 1998 Jan 12; 158(1):26-32. PubMed ID: 9437375
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G, Annis IE, Farley JF, Mahendraratnam N, Hickson RP, Stürmer T, Robinson JG.
    Pharmacotherapy; 2018 Jan 12; 38(1):29-41. PubMed ID: 29059475
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
    Preston RA, Afshartous D, Garg D, Medrano S, Alonso AB, Rodriguez R.
    Hypertension; 2009 May 12; 53(5):754-60. PubMed ID: 19307466
    [Abstract] [Full Text] [Related]

  • 18. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar 12; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.